Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KNSA NASDAQ:MRSN NASDAQ:OMER NASDAQ:PRAX NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$51.89+0.6%$50.50$26.27▼$59.87$3.97B0.12511,503 shs362,761 shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsOMEROmeros$8.73-14.2%$12.18$2.95▼$17.65$736.78M2.521.69 million shs7.78 million shsPRAXPraxis Precision Medicines$266.58+7.5%$319.32$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsSTOKStoke Therapeutics$29.82+1.6%$32.24$11.17▼$40.22$1.83B1.17526,191 shs478,898 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International+4.69%+4.77%-13.28%+12.67%+70.68%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+205.78%OMEROmeros-0.20%-0.68%-31.03%-9.03%+181.22%PRAXPraxis Precision Medicines+3.04%-6.33%-27.74%-15.64%+456.01%STOKStoke Therapeutics+3.09%-2.52%-9.63%-11.54%+155.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$51.89+0.6%$50.50$26.27▼$59.87$3.97B0.12511,503 shs362,761 shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsOMEROmeros$8.73-14.2%$12.18$2.95▼$17.65$736.78M2.521.69 million shs7.78 million shsPRAXPraxis Precision Medicines$266.58+7.5%$319.32$37.19▼$366.52$6.91B2.71467,933 shs423,170 shsSTOKStoke Therapeutics$29.82+1.6%$32.24$11.17▼$40.22$1.83B1.17526,191 shs478,898 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International+4.69%+4.77%-13.28%+12.67%+70.68%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+205.78%OMEROmeros-0.20%-0.68%-31.03%-9.03%+181.22%PRAXPraxis Precision Medicines+3.04%-6.33%-27.74%-15.64%+456.01%STOKStoke Therapeutics+3.09%-2.52%-9.63%-11.54%+155.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKNSAKiniksa Pharmaceuticals International 2.89Moderate Buy$60.8617.28% UpsideMRSNMersana Therapeutics 1.88Reduce$25.92-10.88% DownsideOMEROmeros 2.83Moderate Buy$40.33362.01% UpsidePRAXPraxis Precision Medicines 2.95Moderate Buy$572.72114.84% UpsideSTOKStoke Therapeutics 2.73Moderate Buy$41.8340.29% UpsideCurrent Analyst Ratings BreakdownLatest MRSN, KNSA, STOK, OMER, and PRAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/8/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/2/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/2/2026PRAXPraxis Precision Medicines TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026PRAXPraxis Precision Medicines Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$715.00 ➝ $616.006/2/2026PRAXPraxis Precision Medicines OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $650.006/2/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.00 ➝ $810.006/2/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$420.00 ➝ $374.006/2/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderperform$166.00 ➝ $162.006/2/2026PRAXPraxis Precision Medicines Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$433.00 ➝ $400.006/2/2026PRAXPraxis Precision Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1,245.00 ➝ $1,201.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKNSAKiniksa Pharmaceuticals International$677.56M5.89$0.80 per share64.98$7.44 per share6.97MRSNMersana Therapeutics$33.18M4.38N/AN/A($1.92) per share-15.15OMEROmerosN/AN/A$1.60 per share5.45($1.71) per shareN/APRAXPraxis Precision Medicines$8.55M869.27N/AN/A$34.85 per share7.65STOKStoke Therapeutics$184.42M10.07N/AN/A$6.17 per share4.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKNSAKiniksa Pharmaceuticals International$59.01M$0.9057.3130.52N/A9.69%13.26%9.86%7/28/2026 (Estimated)MRSNMersana Therapeutics-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/AOMEROmeros-$3.35M$0.7012.47N/AN/AN/A-102.16%64.87%8/13/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-43.02%-40.22%8/3/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)Latest MRSN, KNSA, STOK, OMER, and PRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026OMEROmeros-$0.40-$0.24+$0.16$0.62$4.19 million$9.89 million5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/31/2026Q4 2025OMEROmeros-$0.55$3.14+$3.69$0.98$40.15 millionN/A3/16/2026Q4 2025STOKStoke TherapeuticsN/A-$0.97N/A-$0.97N/A$1.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKNSAKiniksa Pharmaceuticals InternationalN/A3.793.33MRSNMersana TherapeuticsN/A1.391.39OMEROmerosN/A3.033.03PRAXPraxis Precision MedicinesN/A15.8815.88STOKStoke TherapeuticsN/A8.998.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKNSAKiniksa Pharmaceuticals International53.95%MRSNMersana Therapeutics93.92%OMEROmeros48.79%PRAXPraxis Precision Medicines67.84%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipKNSAKiniksa Pharmaceuticals International51.98%MRSNMersana Therapeutics13.00%OMEROmeros12.90%PRAXPraxis Precision Medicines2.70%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableMRSNMersana Therapeutics1505.00 million4.35 millionOptionableOMEROmeros21072.38 million63.04 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableSTOKStoke Therapeutics10062.28 million56.37 millionOptionableMRSN, KNSA, STOK, OMER, and PRAX HeadlinesRecent News About These CompaniesStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comStoke Therapeutics Stockholders Approve Directors and Governance ItemsJune 4, 2026 | tipranks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 4, 2026 | zacks.comBarry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 4, 2026 | insidertrades.comStoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesJune 1, 2026 | insidermonkey.comStoke Therapeutics to Present at Upcoming Investor Conferences in JuneMay 29, 2026 | finance.yahoo.comUBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOKMay 22, 2026 | marketbeat.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?May 21, 2026 | zacks.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 | businesswire.comHC Wainwright Analysts Boost Earnings Estimates for STOKMay 13, 2026 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 12, 2026 | finance.yahoo.comStoke Therapeutics, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Guardant Health (GH) and Stoke Therapeutics (STOK)May 10, 2026 | theglobeandmail.comStoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balanceMay 8, 2026 | seekingalpha.comStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesMay 8, 2026 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2026 | zacks.comStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesMay 2, 2026 | finance.yahoo.comStoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet SyndromeMay 1, 2026 | seekingalpha.comStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPalantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceBy Thomas Hughes | June 1, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026Kiniksa Pharmaceuticals Still Has Room to Run After 100% RallyBy Chris Markoch | May 23, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026MRSN, KNSA, STOK, OMER, and PRAX Company DescriptionsKiniksa Pharmaceuticals International NASDAQ:KNSA$51.89 +0.31 (+0.60%) Closing price 04:00 PM EasternExtended Trading$51.81 -0.08 (-0.15%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Mersana Therapeutics NASDAQ:MRSNMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Omeros NASDAQ:OMER$8.73 -1.45 (-14.24%) Closing price 04:00 PM EasternExtended Trading$8.88 +0.15 (+1.75%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Praxis Precision Medicines NASDAQ:PRAX$266.58 +18.60 (+7.50%) Closing price 04:00 PM EasternExtended Trading$270.00 +3.42 (+1.28%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$29.82 +0.46 (+1.57%) Closing price 04:00 PM EasternExtended Trading$29.84 +0.02 (+0.08%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
